OncoMatch/Clinical Trials/NCT05894018
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Is NCT05894018 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Fluzoparib for sarcoma,soft tissue.
Treatment: Fluzoparib — To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy (doxorubicin, ifosfamide) — first-line
Received systemic therapy (such as standard treatment: doxorubicin plus ifosfamide) ± surgical resection as the first-line treatment
Cannot have received: chemotherapy, surgery
Exception: less than 4 weeks after completion of treatment (last dose) and prior to study dosing; or patients who have not recovered from adverse events (other than alopecia) caused by prior treatment to ≤ CTCAE grade 1
Patients who have received prior chemotherapy, surgery, less than 4 weeks after completion of treatment (last dose) and prior to study dosing; or patients who have not recovered from adverse events (other than alopecia) caused by prior treatment to ≤ CTCAE grade 1
Cannot have received: external radiotherapy
Prior external radiotherapy to the lesion
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN; Alkaline phosphatase (AKP) ≤2.5×ULN
Cardiac function
No NYHA class 2 or higher heart failure, unstable angina, myocardial infarction within 1 year, clinically significant arrhythmias requiring treatment or intervention, QTc>450ms (men), QTc>470ms (women)
Normal function of important organs, including: Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously, and if FT3 and FT4 levels are normal, patients can be included); Bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN; Alkaline phosphatase (AKP) ≤2.5×ULN; Serum creatinine ≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05894018 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, surgery, external radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages